PRESS RELEASES
05/2022

Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022

Company Adopts Denifanstat as Non-Proprietary Name for TVB-2640 San Mateo, California, May 4, 2022 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally discovered, selective fatty…
Read More
PRESS RELEASES
11/2021

New Data from Sagimet’s Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640’s Positive Effect Across Patients with NASH in the U.S. and China

San Mateo, California, November 12, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will…
Read More
PRESS RELEASES
10/2021

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting 2021

FOR IMMEDIATE RELEASE San Mateo, California, October 4, 2021– Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results from its Phase 2 FASCINATE-1 trial of TVB-2640 in patients…
Read More
PRESS RELEASES
08/2021

Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today…
Read More
PRESS RELEASES
07/2021

Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat

San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology…
Read More
NASH
07/2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Gastroenterology
Read More
PRESS RELEASES
05/2021

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors

San Mateo, California, May 3, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of…
Read More
PRESS RELEASES
04/2021

Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress™ 2021 (EASL)

San Mateo, California, April 23, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that additional clinical…
Read More
Oncology
04/2021

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

EClinicalMedicine
Read More
PRESS RELEASES
03/2021

Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH

In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH)  San Mateo, California, March 16, 2021 – Sagimet Biosciences Inc., a…
Read More